Revisit Every OncLive On Air Episode From September 2026

In case you missed any, below is a recap of the episodes of OncLive On Air^® that aired in September 2026. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!

A Breast Radiologist Breaks Down Breast Cancer Screening Guidelines: With Sara Nunnery, MD, MSCI; and Dana Bonaminio, MD

In this episode of Breast Cancer Briefing, host Sara Nunnery, MD, MSCI, of Tennessee Oncology in Nashville, sat down with breast radiologist Dana Bonaminio, MD, of Ascension Saint Thomas in Nashville, to unpack breast cancer screening amid recent guideline updates. Their conversation spanned breast density as an independent risk factor, contrast-enhanced mammography, the case for annual mammography beginning at age 40, and artificial intelligence (AI)–based risk assessment tools, such as Clairity Breast.

How Compassion and Research Build Palliative Care for the Precision Oncology Era

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, spoke with Laura A. Petrillo, MD, of Massachusetts General Hospital and Harvard Medical School in Boston, about her path from a science-curious student to a leader in palliative care research. Dr Petrillo reflected on how targeted agents, checkpoint inhibitors, and CAR T-cell therapy have reshaped the patient experience and spotlighted the POISE study (NCT04900935), which blends palliative care with survivorship.

Metastatic Non–Small Cell Lung Cancer 2026 Update

In this episode, OncLive On Air partnered with Two Onc Docs hosts Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis, and Karine Tawagi, MD, of the University of Illinois in Chicago, for a comprehensive, board-focused review of metastatic non–small cell lung cancer (NSCLC) diagnosis and management for 2026. They walked through molecular workup, first-line options across EGFR-, ALK-, ROS1-, and other driver-positive disease, HER2-directed therapies, and treatment stratified by PD-L1 status and histology in driver-negative disease.

Oncology’s AI Adoption Hinges on Weighing Benefits vs Risks and Confronting Limitations

In this episode of Breast Cancer Briefing, Dr Nunnery sat down with Matthew Kurian, MD, of St. Elizabeth Healthcare in Edgewood, Kentucky, to examine the role of AI in oncology. Dr Kurian distinguished generative large language models from retrieval-grounded tools, weighed the benefits and pitfalls of AI scribes and FDA-authorized devices, such as Clairity Breast, and called for prospective validation before these tools are integrated into guidelines.

Fast-Moving Treatment Advances Shape B-Cell Lymphoma Care

In this episode of Oncology Unplugged, host Chandler Park, MD, of Norton Cancer Institute in Louisville, Kentucky, was joined by Joshua Brody, MD, of the Mount Sinai Tisch Cancer Center in New York, New York, to survey the fast-moving B-cell non-Hodgkin lymphoma treatment landscape. They discussed the phase 3 frontMIND trial (NCT04824092) of tafasitamab-cxix (Monjuvi) and lenalidomide (Revlimid) added to R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) in frontline diffuse large B-cell lymphoma, CAR T-cell therapy and bispecific antibody combinations in relapsed disease, and the evolving mantle cell lymphoma paradigm, including the FDA approval of sonrotoclax (Beqalzi).

Pancreatic Cancer Experts Map Treatment Sequencing With Liposomal Irinotecan and Beyond

In this episode of OncLive On Air, Raji Shameem, MD, of Orlando Health in Florida, and Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center in Houston, discussed evolutions in the pancreatic cancer treatment landscape. They explored the role of liposomal irinotecan (Onivyde), the FDA approval of daraxonrasib (Rasonque) for patients with metastatic disease, and novel agents in development.

INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

In this episode of OncLive On Air, Davide Melisi, MD, PhD, of the University of Verona in Italy, discussed the investigational oral KRAS G12D inhibitor INCB161734, its mechanism of action, and early data with the agent. He also outlined the ongoing phase 3 DAWN-303 trial (NCT07522073) in patients with KRAS G12D–mutated metastatic pancreatic ductal adenocarcinoma and how the agent might fit into sequencing alongside the FDA approval of daraxonrasib for patients with metastatic pancreatic cancer.

Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC

In this episode of OncLive On Air, Narjust Florez, MD, of Dana-Farber Cancer Institute and Harvard Medical School in Boston, and Jonathan Wesley Riess, MD, MS, of the University of California Davis Health in Sacramento, clarified the distinction between HER2 overexpression and HER2 mutations in NSCLC. They reviewed the use of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2 immunohistochemistry 3+ disease, efficacy data from the DESTINY-Lung studies, and toxicity management, including vigilance for interstitial lung disease.

Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer

In this episode of OncLive On Air, Nataliya Uboha, MD, PhD, of the University of Wisconsin School of Medicine in Madison, broke down the August 2026 FDA approval of zanidatamab (Ziihera)–based regimens for first-line HER2-positive locally advanced or metastatic gastric cancer. She unpacked supporting data from the phase 3 HERIZON-GEA-01 trial (NCT05152147) and discussed where zanidatamab fits alongside PD-1 inhibitors, such as tislelizumab (Tevimbra), and other options like trastuzumab (Herceptin).

Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

In this episode of Oncology Unplugged, Dr Park was joined by Pashtoon Kasi, MD, MS, of City of Hope Orange County in Irvine, California, to discuss the rise of neoadjuvant immunotherapy as a paradigm shift in colorectal cancer management. They covered the biology of mismatch repair–deficient/microsatellite instability–high tumors, data from the phase 3 ATOMIC trial (NCT02912559) and the NICHE trial series, and how Dr Kasi’s NEST trials are showing the activity of botensilimab plus balstilimab in mismatch repair–proficient/microsatellite stable disease.

Exploring the FDA Approval of Optune Pax and What It Means for Locally Advanced Pancreatic Cancer

In this episode of OncLive On Air, Philip A. Philip, MD, of the Henry Ford Cancer Institute in Detroit, Michigan, discussed the February 2026 FDA approval of Optune Pax for locally advanced pancreatic cancer. He reviewed key data from the phase 3 PANOVA-3 trial (NCT03377491), which evaluated the modality in combination with gemcitabine and nab-paclitaxel (Abraxane), and looked ahead to combination regimens with newly approved agents, such as daraxonrasib (Rasonque).

Unpacking Data and Upcoming Developments for Olverembatinib in CML

In this episode of OncLive On Air, Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, and Dennis Kim, MD, of the University of Toronto in Canada, discussed the third-generation TKI olverembatinib (HQP1351) and its potential advantages in chronic myeloid leukemia and acute lymphoblastic leukemia. They reviewed data presented at the 2026 ASCO Annual Meeting, including the phase 1b HQP1351CU101 trial (NCT04260022), and previewed next steps, such as the ongoing phase 3 POLARIS-2 trial (NCT06423911).

Dissecting Diagnostic and Management Factors in Systemic Mastocytosis

In this episode of OncLive On Air, Tracy I. George, MD, of ARUP Laboratories and the University of Utah in Salt Lake City, offered a pathologist’s perspective on the diagnosis and evolving management of systemic mastocytosis. She highlighted the key diagnostic hallmarks, how pathologists collaborate across multidisciplinary teams, and how agents like bezuclastinib (CGT9486) and avapritinib (Ayvakit) are changing the treatment paradigm.

Start Earlier and Find Your Community: Navigating the Fellowship-to-Faculty Transition Through Mentorship and Specialty-Focused Meetings

In this episode of OncLive On Air, Jacqueline Aredo, MD, of Mass General Brigham Cancer Institute, and Benjamin Bleiberg, MD, of the University of Pennsylvania Perelman School of Medicine in Philadelphia, reflected on the experiences and relationships that shaped their transitions from fellowship into their first faculty positions in thoracic oncology. They discussed the value of smaller, specialty-focused meetings, such as the ASCO Fellows Forum, in building professional community and shared practical advice for navigating the fellowship-to-faculty job search.

Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape

In this episode of OncLive On Air, Alissa Cooper, MD, of Dana-Farber Cancer Institute and Harvard Medical School, spoke with Noura Choudhury, MD, of the University of Chicago in Illinois, about the evolving role of DLL3-targeting T-cell engagers in small cell lung cancer. They focused on tarlatamab-dlle (Imdelltra) and the phase 3 DeLLphi-305 trial (NCT06211036), the investigational bispecific obrixtamig, DLL3 immunohistochemistry testing in practice, and risk stratification for toxicities such as cytokine release syndrome.

Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma

In this episode of OncLive On Air, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, of the Cleveland Clinic in Ohio, and Sikander Ailawadhi, MD, of Mayo Clinic in Rochester, Minnesota, discussed evolving administration strategies for multiple myeloma therapies. In the first episode of a 3-part series, they outlined the shift toward subcutaneous administration of anti-CD38 monoclonal antibodies and the significance of the July 2026 FDA approval of isatuximab-irfc (Sarclisa Escena) for subcutaneous injection, including delivery via the CirCLIQ on-body system.

Resistance Patterns Shape FGFR Inhibitor Sequencing in Cholangiocarcinoma

In this episode of OncLive On Air, Arndt Vogel, MD, of the University of Toronto and the UHN–Princess Margaret Cancer Centre in Canada, made the case for sequential FGFR inhibition in FGFR2 fusion–positive cholangiocarcinoma. He explained how on-target resistance mutations and the differing binding properties of agents such as pemigatinib (Pemazyre), futibatinib (Lytgobi), and the more selective tinengotinib (TT-00420) support using them in sequence, and emphasized early RNA-based next-generation sequencing and the emerging role of circulating tumor DNA.

FDA Approval Insights: Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma

In this episode of OncLive On Air, Kim A. Reiss Binder, MD, of the Hospital of the University of Pennsylvania in Philadelphia, discussed the August 2026 FDA approval of daraxonrasib (Rasonque) for adults with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multi-agent systemic therapy. She also reviewed key efficacy data from the pivotal phase 3 RASolute 302 trial (NCT06625320) that supported the decision.